U.S. vaccine market to hit $17B by 2018; Military research probes HIV weaknesses to find vaccine;

> Scientists from the U.S. Military HIV Research Program in Maryland think they are finding weaknesses in HIV that can lead to an effective vaccine. Story

> A study by Transparency Market Research shows the U.S. vaccines market will reach $17.4 billion by 2018. More

> Austrian biotech Intercell launched its JEEV vaccine to combat Japanese encephalitis in India. News

> In New Zealand, doctors are recording a spike in demand for the meningococcal C vaccine, after a 12-year-old girl succumbed to it and died. Story

> Interim results from a Phase II trial conducted in India to test a tuberculosis vaccine are expected to be released "soon," according to The Hindu. Article

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.